IFNG and melanoma: We validated this method by inducing interferon gamma (IFNγ)-dependent HLA-I peptide alterations (24) and applied this workflow to reveal quantitative changes in the immunopeptidome of melanoma cell lines upon treatment with the BRAFi/MEKi combination vemurafenib and cobimetinib and the MEKi trametinib alone and compared the immunopeptidomes of a resistant and a non-resistant variant of a melanoma cell line.